- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00809211
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well nilotinib works in treating patients with newly diagnosed chronic phase chronic myelogenous leukemia.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To establish the complete cytogenetic response rate at 6 months in patients with newly diagnosed Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia treated with nilotinib.
Secondary
- To establish the complete cytogenetic response rate at 3, 9, 12, 18, and 24 months in these patients.
- To establish the molecular response rate at 3, 6, 9, 12, 18, and 24 months in these patients.
- To establish the safety of this drug in these patients.
- To correlate pharmacokinetic data with response rate and toxicity.
- To correlate Bcr-Abl results using GeneXpert with Bcr-Abl results using international standardized quantitative PCR.
- To estimate the prevalence of Bcr-Abl mutations prior to and during treatment.
OUTLINE: This is a multicenter study.
Patients receive oral nilotinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Peripheral blood and bone marrow samples are collected periodically for mutation analysis, Bcr-Abl analysis by quantitative PCR, metaphase cytogenetics, and pharmacokinetic analysis.
After completion of study therapy, patients are followed every 3 months for 2 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Universitätsklinikum Charité Berlin
-
-
-
-
-
Belfast, Ireland
- Belfast City Hospital
-
Dublin, Ireland, 8
- St. James's Hospital
-
Galway, Ireland
- University College Hospital
-
-
-
-
-
Tel Hashomer, Israel
- Chaim Sheba Medical Centre
-
-
-
-
Texas
-
San Antonio, Texas, United States, 78229-3900
- University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Cytogenetically confirmed chronic myelogenous leukemia (CML) by standard conventional cytogenetic analysis of bone marrow*
- Newly diagnosed disease (within the past 6 months) NOTE: *FISH cannot be used
In chronic phase, as defined by the following:
- Less than 15% blasts in peripheral blood and bone marrow
- Less than 30% blasts plus promyelocytes in peripheral blood and bone marrow
- Less than 20% basophils in peripheral blood
- Platelet count ≥ 100,000/mm^3
- No evidence of extramedullary leukemic involvement, except for hepatosplenomegaly
Philadelphia chromosome-positive disease as demonstrated by (9;22) translocation (presence of Bcr-Abl)
- A review of ≥ 20 metaphases is required
- No previously documented T315I mutations
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- AST and ALT < 2.5 times ULN
- Estimated glomerular filtration rate ≥ 30 mL/min
- Serum amylase and lipase ≤ 1.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN (unless related to CML)
- Potassium ≥ lower limit of normal (LLN)
- Magnesium ≥ LLN
- Phosphorous ≥ LLN
- Total calcium ≥ LLN (corrected for serum albumin)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No impaired cardiac function including, but not limited to, any of the following:
- LVEF < 45% or < LLN by ECHO
- Inability to determine the QT interval on ECG
- Complete left bundle branch block
- Congenital long QT syndrome or a known family history of long QT syndrome
- History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- Clinically significant resting bradycardia (< 50 beats/min)
- QTc > 450 msec on an average of 3 serial baseline ECGs (using the QTcF formula)
- Clinically documented myocardial infraction within the past 12 months
- Unstable angina within the past 12 months
- Other clinically significant heart disease (e.g., congestive heart failure or uncontrolled hypertension)
- No severe or uncontrolled medical condition (e.g., uncontrolled diabetes or active or uncontrolled infection)
- No history of significant congenital or acquired bleeding disorder unrelated to CML
- No history of non-compliance to medical regimens
- No other primary malignancy unless it is neither currently clinically significant nor requiring active intervention
- No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
- No acute pancreatitis within the past year
- No history of chronic pancreatitis
- No acute or chronic liver, pancreatic, or severe renal disease considered unrelated to CML
PRIOR CONCURRENT THERAPY:
- No prior therapy for CML other than hydroxyurea and/or anagrelide
- Prior imatinib mesylate allowed provided it was administered for ≤ 14 days
- More than 30 days since prior and no other concurrent investigational agents
- More than 4 weeks since prior major surgery and recovered
- No other concurrent anticancer agents, including chemotherapy and biologic agents
- No concurrent strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil)
- No concurrent strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort)
- No concurrent medications that have the potential to prolong QT interval
- No concurrent grapefruit, star fruit, Seville oranges, or their derivatives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nilotinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete cytogenetic response rate at 6 months as assessed by metaphase analysis
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Molecular response rate at 3, 6, 9, 12, 18, and 24 months as assessed by quantitative PCR
Time Frame: 6 months
|
6 months
|
Time to disease progression
Time Frame: 6 months
|
6 months
|
Duration of event-free survival
Time Frame: 6 months
|
6 months
|
Overall toxicity rate
Time Frame: 6 months
|
6 months
|
Correlation of pharmacokinetic data with response rate and toxicity
Time Frame: 6 months
|
6 months
|
Correlation of Bcr-Abl results using GeneXpert with Bcr-Abl results using international standardized quantitative PCR
Time Frame: 6 months
|
6 months
|
Prevalence of Bcr-Abl mutations prior to and during treatment
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mike O'Dwyer, MD, University College London Hospitals
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICORG 08-02
- EUDRACT-2008-004551-30
- EU-20899
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
Clinical Trials on pharmacological study
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Universitätsmedizin MannheimHeidelberg UniversityCompletedLung Cancer | Brain and Central Nervous System TumorsGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Peloton Therapeutics, Inc.CompletedRecurrent GlioblastomaUnited States
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary SyndromeUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico